Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin

被引：67

作者：

Kris, MG

Radford, JE

Pizzo, BA

Inabinet, R

Hesketh, A

Hesketh, PJ

机构：

[1] MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,THORAC ONCOL SERV,NEW YORK,NY 10021

[2] CORNELL UNIV COLL,NEW YORK,NY

[3] WAKE FOREST UNIV,CTR COMPREHENS CANC,WINSTON SALEM,NC 27109

[4] ST ELIZABETHS MED CTR,SECT MED ONCOL,BOSTON,MA

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1997年 / 89卷 / 11期

关键词：

D O I：

10.1093/jnci/89.11.817

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：817 / 818

页数：2

共 13 条

[1] The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist [J].

Beattie, DT ;

Beresford, IJM ;

Connor, HE ;

Marshall, FH ;

Hawcock, AB ;

Hagan, RM ;

Bowers, J ;

Birch, PJ ;

Ward, P .

BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (08) :3149-3157

[2] ANTIEMETIC PROFILE OF A NONPEPTIDE NEUROKININ-NK(1) RECEPTOR ANTAGONIST, CP-99,994, IN FERRETS [J].

BOUNTRA, C ;

BUNCE, K ;

DALE, T ;

GARDNER, C ;

JORDAN, C ;

TWISSELL, D ;

WARD, P .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 249 (01) :R3-R4

[3]

Cunningham D, 1996, ANN ONCOL, V7, P277

[4]

DOCKRAY GJ, 1994, GUT PEPTIDES BIOCH P, P401

[5]

FLORCZYK AP, 1982, CANCER TREAT REP, V66, P187

[6] Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets [J].

Gonsalves, S ;

Watson, J ;

Ashton, C .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 305 (1-3) :181-185

[7] BEHAVIORAL-STUDIES OF EMETIC SENSITIVITY IN THE FERRET [J].

KNOX, AP ;

STROMINGER, NL ;

BATTLES, AH ;

CARPENTER, DO .

BRAIN RESEARCH BULLETIN, 1993, 31 (05) :477-484

[8]

Kris MG, 1996, CANCER, V78, P2193, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2193::AID-CNCR22>3.0.CO

[9]

2-T

[10]

KRIS MG, 1985, CANCER TREAT REP, V69, P1257

← 1 2 →